Fulcrum Therapeutics, Inc. Stock Analysis & AI Score
Fulcrum Therapeutics, Inc. (FULC) has an ST Score of 52.5 (B-), driven by its Growth (A+) and held back by its Sentiment (F). Analysts rate it Buy with a $3.60 price target (-4.9% downside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Fulcrum Therapeutics, Inc. (FULC) has an ST Score of 52.5 (B-), driven by its Growth (A+) and held back by its Sentiment (F). Analysts rate it Buy with a $3.60 price target (-4.9% downside).
- Strongest
- GrowthA+
- Weakest
- SentimentF
All factor grades
- GrowthA+
- Financial StrengthA
- ValuationA-
- ProfitabilityB+
- MomentumC
- ForecastC-
- SentimentF
- Piotroski2/9
Contact
FULC stock: frequently asked questions
What is FULC's ST Score?
Fulcrum Therapeutics, Inc. (FULC) has an ST Score of 52.5 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is FULC a buy, hold, or sell?
Analysts rate FULC a Buy, with a price target of $3.60 (-4.9% vs the current price). Our ST Score grades it B- (52.5/100). The ST Score is a data-driven signal, not a recommendation.
What are FULC's factor grades?
Valuation A-, Profitability B+, Financial Strength A, Momentum C, Growth A+, Forecast C-, Sentiment F.
What is FULC's valuation grade?
Fulcrum Therapeutics, Inc. (FULC) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is FULC's growth grade?
Fulcrum Therapeutics, Inc. (FULC) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is FULC's profitability grade?
Fulcrum Therapeutics, Inc. (FULC) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is FULC's financial strength grade?
Fulcrum Therapeutics, Inc. (FULC) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for FULC?
The average analyst price target for Fulcrum Therapeutics, Inc. (FULC) is $3.60 from 17 analysts, which is -4.9% versus the recent price of $3.79.
What is FULC's Piotroski score?
Fulcrum Therapeutics, Inc. (FULC) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.